Paromomycin

Last updated

Paromomycin
Paromomycin structure.svg
Paromomycin ball-and-stick.png
Clinical data
Trade names Catenulin, Aminosidine, Humatin, others [1]
Other namesmonomycin, aminosidine [2]
AHFS/Drugs.com Monograph
MedlinePlus a601098
License data
Pregnancy
category
  • C
Routes of
administration 		By mouth, intramuscular, topical [3]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Poorly absorbed in the GI tract
Metabolism Not available
Excretion Fecal
Identifiers
  • (2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-
    4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)-
    3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]
    oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-
    3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.028.567 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C23H47N5O18S
Molar mass 713.71 g·mol−1
3D model (JSmol)
  • O=S(=O)(O)O.O([C@H]3[C@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@H]1O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]1N)[C@H]2O)[C@@H](O)[C@H](N)C[C@@H]3N)[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4N)CO
  • InChI=1S/C23H45N5O14.H2O4S/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;1-5(2,3)4/h5-23,29-36H,1-4,24-28H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1 Yes check.svgY
  • Key:LJRDOKAZOAKLDU-UDXJMMFXSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Paromomycin is an antimicrobial used to treat a number of parasitic infections including amebiasis, giardiasis, leishmaniasis, and tapeworm infection. [3] It is a first-line treatment for amebiasis or giardiasis during pregnancy. [3] Otherwise, it is generally a second line treatment option. [3] It is taken by mouth, applied to the skin, or by injection into a muscle. [3]

Contents

Common side effects when taken by mouth include loss of appetite, vomiting, abdominal pain, and diarrhea. [3] When applied to the skin side effects include itchiness, redness, and blisters. [3] When given by injection there may be fever, liver problems, or hearing loss. [3] Use during breastfeeding appears to be safe. [4] Paromomycin is in the aminoglycoside family of medications and causes microbe death by stopping the creation of bacterial proteins. [3]

Paromomycin was discovered in the 1950s from a type of streptomyces and came into medical use in 1960. [1] [4] It is on the World Health Organization's List of Essential Medicines. [5] [6] Paromomycin is available as a generic medication. [7]

Medical uses

It is an antimicrobial used to treat intestinal parasitic infections such as cryptosporidiosis [8] and amoebiasis, [9] and other diseases such as leishmaniasis. [10] Paromomycin was demonstrated to be effective against cutaneous leishmaniasis in clinical studies in the USSR in the 1960s, and in trials with visceral leishmaniasis in the early 1990s. [2]

The route of administration is intramuscular injection and capsule. Paromomycin topical cream with or without gentamicin is an effective treatment for ulcerative cutaneous leishmaniasis, according to the results of a phase-3, randomized, double-blind, parallel group–controlled trial. [11]

Pregnancy and breastfeeding

The medication is poorly absorbed. [12] The effect it may have on the baby is still unknown. [13]

There is limited data regarding the safety of taking paromomycin while breastfeeding but because the drug is poorly absorbed minimal amounts of drug will be secreted in breastmilk. [14]

HIV/AIDS

There is limited evidence that paromomycin can be used in persons coinfected with HIV and Cryptosporidium. A few small trials have showed a reduction in oocyst shedding after treatment with paromomycin. [15]

Adverse effects

The most common adverse effects associated with paromomycin sulfate are abdominal cramps, diarrhea, heartburn, nausea, and vomiting. Long-term use of paromomycin increases the risk for bacterial or fungal infection. Signs of overgrowth include white patches in the oral cavities. Other less common adverse events include myasthenia gravis, kidney damage, enterocolitis, malabsorption syndrome, eosinophilia, headache, hearing loss, ringing in the ear, itching, severe dizziness, and pancreatitis. [16]

Interactions

Paromomycin belongs to the aminoglycoside drug class and therefore are toxic to the kidneys and to ears. These toxicities are additive and are more likely to occur when used with other drugs that cause ear and kidney toxicity. [15] Concurrent use of foscarnet increases the risk of kidney toxicity. [17] Concurrent use of colistimethate and paromomycin can cause a dangerous slowing of breathing known as respiratory depression, and should be done with extreme caution if necessary. [17] When used with systemic antibiotics such as paromomycin, the cholera vaccine can cause an immune response. [17] Use with strong diuretics, which can also harm hearing, should be avoided. [18] Paromomycin may have dangerous reactions when used with the paralytic succinylcholine by increasing its neuromuscular effects. [19]

There are no known food or drink interactions with paromomycin. [17]

Mechanism

Paromomycin is a protein synthesis inhibitor in nonresistant cells by binding to 16S ribosomal RNA. [20] This broad-spectrum antibiotic soluble in water, is very similar in action to neomycin. Antimicrobial activity of paromomycin against Escherichia coli and Staphylococcus aureus has been shown. [21] Paromomycin works as an antibiotic by increasing the error rate in ribosomal translation. Paromomycin binds to a RNA loop, where residues A1492 and A1493 are usually stacked, and expels these two residues. These two residues are involved in detection of correct Watson-Crick pairing between the codon and anti codon. When correct interactions are achieved, the binding provides energy to expel the two residues. Paromomycin binding provides enough energy for residue expulsion and thus results in the ribosome incorporating the incorrect amino acid into the nascent peptide chain. [22]

Pharmacokinetics

Absorption

GI absorption is poor. Any obstructions or factors which impair GI motility may increase the absorption of the drug from the digestive tract. In addition, any structural damage, such as lesions or ulcerations, will tend to increase drug absorption. [23]

For intramuscular (IM) injection, the absorption is rapid. Paromomycin will reach peak plasma concentration within one hour following IM injection. [3] The in-vitro and in-vivo activities parallel those of neomycin. [24]

Elimination

Almost 100% of the oral dose is eliminated unchanged via feces. Any absorbed drug will be excreted in urine. [25]

History

Paromomycin was discovered in the 1950s amongst the secondary metabolites of a variety of Streptomyces then known as Streptomyces krestomuceticus, now known as Streptomyces rimosus . It came into medical use in 1960. [1] [4]

Related Research Articles

<span class="mw-page-title-main">Ampicillin</span> Antibiotic

Ampicillin is an antibiotic belonging to the aminopenicillin class of the penicillin family. The drug is used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously.

<span class="mw-page-title-main">Amoxicillin</span> Beta-lactam antibiotic

Amoxicillin is an antibiotic medication belonging to the aminopenicillin class of the penicillin family. The drug is used to treat bacterial infections such as middle ear infection, strep throat, pneumonia, skin infections, odontogenic infections, and urinary tract infections. It is taken by mouth, or less commonly by injection.

<span class="mw-page-title-main">Chloramphenicol</span> Antibiotic

Chloramphenicol is an antibiotic useful for the treatment of a number of bacterial infections. This includes use as an eye ointment to treat conjunctivitis. By mouth or by injection into a vein, it is used to treat meningitis, plague, cholera, and typhoid fever. Its use by mouth or by injection is only recommended when safer antibiotics cannot be used. Monitoring both blood levels of the medication and blood cell levels every two days is recommended during treatment.

<span class="mw-page-title-main">Pentamidine</span> Medical antimicrobial drug

Pentamidine is an antimicrobial medication used to treat African trypanosomiasis, leishmaniasis, Balamuthia infections, babesiosis, and to prevent and treat pneumocystis pneumonia (PCP) in people with poor immune function. In African trypanosomiasis it is used for early disease before central nervous system involvement, as a second line option to suramin. It is an option for both visceral leishmaniasis and cutaneous leishmaniasis. Pentamidine can be given by injection into a vein or muscle or by inhalation.

<span class="mw-page-title-main">Streptomycin</span> Aminoglycoside antibiotic

Streptomycin is an antibiotic medication used to treat a number of bacterial infections, including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever. For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide. It is administered by injection into a vein or muscle.

<span class="mw-page-title-main">Gentamicin</span> Antibiotic medication

Gentamicin is an antibiotic used to treat several types of bacterial infections. This may include bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. It is not effective for gonorrhea or chlamydia infections. It can be given intravenously, by intramuscular injection, or topically. Topical formulations may be used in burns or for infections of the outside of the eye. It is often only used for two days until bacterial cultures determine what specific antibiotics the infection is sensitive to. The dose required should be monitored by blood testing.

<span class="mw-page-title-main">Amphotericin B</span> Antifungal and antiparasitaric chemical compound

Amphotericin B is an antifungal medication used for serious fungal infections and leishmaniasis. The fungal infections it is used to treat include mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis. For certain infections it is given with flucytosine. It is typically given intravenously.

<span class="mw-page-title-main">Colistin</span> Antibiotic

Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.

<span class="mw-page-title-main">Amoxicillin/clavulanic acid</span> Combination antibiotic drug

Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, sold under the brand name Augmentin, among others, is an antibiotic medication used for the treatment of a number of bacterial infections. It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Daptomycin</span> Antibiotic

Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

<span class="mw-page-title-main">Kanamycin A</span> Antibiotic

Kanamycin A, often referred to simply as kanamycin, is an antibiotic used to treat severe bacterial infections and tuberculosis. It is not a first line treatment. It is used by mouth, injection into a vein, or injection into a muscle. Kanamycin is recommended for short-term use only, usually from 7 to 10 days. As with most antibiotics, it is ineffective in viral infections.

<span class="mw-page-title-main">Tigecycline</span> Chemical compound

Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.

<span class="mw-page-title-main">Tobramycin</span> Chemical compound

Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas.

<span class="mw-page-title-main">Amikacin</span> Antibiotic medication

Amikacin is an antibiotic medication used for a number of bacterial infections. This includes joint infections, intra-abdominal infections, meningitis, pneumonia, sepsis, and urinary tract infections. It is also used for the treatment of multidrug-resistant tuberculosis. It is used by injection into a vein using an IV or into a muscle.

<span class="mw-page-title-main">Capreomycin</span> Pharmaceutical drug

Capreomycin is an antibiotic which is given in combination with other antibiotics for the treatment of tuberculosis. Specifically it is a second line treatment used for active drug resistant tuberculosis. It is given by injection into a vein or muscle.

<span class="mw-page-title-main">Sodium stibogluconate</span> Pharmaceutical drug

Sodium stibogluconate, sold under the brand name Pentostam among others, is a medication used to treat leishmaniasis. This includes leishmaniasis of the cutaneous, visceral, and mucosal types. Some combination of miltefosine, paramycin and liposomal amphotericin B, however, may be recommended due to issues with resistance. It is given by injection.

Antiprotozoal agents is a class of pharmaceuticals used in treatment of protozoan infection.

<span class="mw-page-title-main">Miltefosine</span> Phospholipid drug

Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris. This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal. It may be used with liposomal amphotericin B or paromomycin. It is taken by mouth.

<span class="mw-page-title-main">Diloxanide</span> Medication for amoebic gut infections

Diloxanide is a medication used to treat amoeba infections. In places where infections are not common, it is a second line treatment after paromomycin when a person has no symptoms. For people who are symptomatic, it is used after treatment with metronidazole or tinidazole. It is taken by mouth.

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

References

  1. 1 2 3 "Paromomycin". Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013. p. 21p. ISBN   978-0-8155-1856-3. Archived from the original on 20 December 2016.
  2. 1 2 Neal RA, Murphy AG, Olliaro P, Croft SL (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (2): 223–225. doi:10.1016/0035-9203(94)90307-7. PMID   8036682.
  3. 1 2 3 4 5 6 7 8 9 10 "Paromomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 17 November 2016. Retrieved 3 December 2016.
  4. 1 2 3 Davidson RN, den Boer M, Ritmeijer K (July 2009). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene. 103 (7): 653–660. doi:10.1016/j.trstmh.2008.09.008. PMID   18947845.
  5. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  7. ↑ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 54. ISBN   978-1-284-05756-0.
  8. ↑ Sweetman S, ed. (2002). Martindale: The Complete Drug Reference (33rd ed.). London: Pharmaceutical Press. ISBN   978-0-85369-499-1.
  9. ↑ " paromomycin " at Dorland's Medical Dictionary
  10. ↑ Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (June 2007). "Injectable paromomycin for Visceral leishmaniasis in India". The New England Journal of Medicine. 356 (25): 2571–2581. doi: 10.1056/NEJMoa066536 . PMID   17582067.
  11. ↑ Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al. (February 2013). "Topical paromomycin with or without gentamicin for cutaneous leishmaniasis". The New England Journal of Medicine. 368 (6): 524–532. doi: 10.1056/NEJMoa1202657 . PMID   23388004.
  12. ↑ Sweet RL, Gibbs RS (2009). "Parasitic Disease in Pregnancy". Infectious Diseases of the Female Genital Tract. Lippincott Williams & Wilkins. p. 364. ISBN   978-0-7817-7815-2. Archived from the original on 7 November 2016.
  13. ↑ Abramowicz M, ed. (2015). Handbook of Antimicrobial Therapy. New Rochelle, New York: The Medical Letter. p. 468. ISBN   978-0-9815278-8-8.
  14. ↑ "Paromomycin Use During Pregnancy". Drugs.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
  15. 1 2 Bennett JE, Blaser MJ, Dolin R (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases (Eighth ed.). Philadelphia, PA: Saunders. ISBN   978-1-4557-4801-3.
  16. ↑ "paromomycin oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". WebMD. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
  17. 1 2 3 4 "Micromedex".
  18. ↑ Grayson ML, ed. (2012). "Agents Active Against Intestinal and Intra-Abdominal Protozoa: Paromomycin". Kucers' the use of antibiotics a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs (6th ed.). Boca Raton, FL: CRC Press. p. 2144. ISBN   978-1-4441-4752-0. Archived from the original on 8 September 2017.
  19. ↑ Aschenbrenner DS (2008). Drug therapy in nursing. US: Wolters Kluwer Health. ISBN   978-1-60547-270-6.
  20. ↑ Vicens Q, Westhof E (August 2001). "Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site". Structure. 9 (8): 647–658. doi: 10.1016/S0969-2126(01)00629-3 . PMID   11587639.
  21. ↑ "Paromomycin" (PDF). Toku-E. 12 January 2010. Archived from the original (PDF) on 26 April 2014. Retrieved 11 June 2012.
  22. ↑ Voet D, Voet JG (2011). "Ribosomes". Biochemistry (4th ed.). New York: John Wiley & Sons Inc. p. 1397. ISBN   978-0-470-57095-1.
  23. ↑ Paromomycin sulfate capsules, USP prescribing information (Report). Detroit, MI: Caraco Pharmaceutical Laboratories. March 1997.
  24. ↑ "Paromomycin". DrugBank. 17 August 2016. Archived from the original on 10 November 2016.
  25. ↑ Iwaki S, Honke K, Nishida N, Taniguchi N (July 1981). "[The absorption, excretion and influence on bowel flora of oral paromomycin sulfate (author's transl)]". The Japanese Journal of Antibiotics (in Japanese). 34 (7): 1078–81. PMID   7321186.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.